The GEIA study aims to investigate the impact of HLA-G tumor expression on the efficacy of cancer immunotherapy in patients with solid cancers to evaluate the presence of resistance to the current immunocheckpoint inhibitor strategy (NCT04300088). Here, HLA-G is linked to neoplasm.